221 related articles for article (PubMed ID: 27826881)
1. Bone Fractures with Sodium-Glucose Co-transporter-2 Inhibitors: How Real is the Risk?
Mannucci E; Monami M
Drug Saf; 2017 Feb; 40(2):115-119. PubMed ID: 27826881
[TBL] [Abstract][Full Text] [Related]
2. Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes.
Trujillo JM; Nuffer WA
Pharmacotherapy; 2017 Apr; 37(4):481-491. PubMed ID: 28102030
[TBL] [Abstract][Full Text] [Related]
3. Do sodium-glucose cotransporter 2 inhibitors lead to fracture risk? A pharmacovigilance real-world study.
Zhao B; Shen J; Zhao J; Pan H
J Diabetes Investig; 2021 Aug; 12(8):1400-1407. PubMed ID: 33325646
[TBL] [Abstract][Full Text] [Related]
4. Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus.
Carlson CJ; Santamarina ML
Expert Opin Drug Saf; 2016 Oct; 15(10):1401-12. PubMed ID: 27449721
[TBL] [Abstract][Full Text] [Related]
5. Canagliflozin triggers the FGF23/1,25-dihydroxyvitamin D/PTH axis in healthy volunteers in a randomized crossover study.
Blau JE; Bauman V; Conway EM; Piaggi P; Walter MF; Wright EC; Bernstein S; Courville AB; Collins MT; Rother KI; Taylor SI
JCI Insight; 2018 Apr; 3(8):. PubMed ID: 29669938
[TBL] [Abstract][Full Text] [Related]
6. Dapagliflozin for the treatment of type 1 diabetes mellitus.
Pafili K; Maltezos E; Papanas N
Expert Opin Investig Drugs; 2017 Jul; 26(7):873-881. PubMed ID: 28587531
[TBL] [Abstract][Full Text] [Related]
7. Adverse effects of SGLT2 inhibitors on bone health.
Blau JE; Taylor SI
Nat Rev Nephrol; 2018 Aug; 14(8):473-474. PubMed ID: 29875481
[TBL] [Abstract][Full Text] [Related]
8. The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus.
Alba M; Xie J; Fung A; Desai M
Curr Med Res Opin; 2016 Aug; 32(8):1375-85. PubMed ID: 27046479
[TBL] [Abstract][Full Text] [Related]
9. Possible adverse effects of SGLT2 inhibitors on bone.
Taylor SI; Blau JE; Rother KI
Lancet Diabetes Endocrinol; 2015 Jan; 3(1):8-10. PubMed ID: 25523498
[No Abstract] [Full Text] [Related]
10. Sodium glucose co-transporter inhibitors for the management of diabetes mellitus: an opinion paper from the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy.
Clements JN; Whitley HP; D'Souza JJ; Gross B; Hess R; Reece S; Gentry C; Shealy K
Curr Med Res Opin; 2015; 31(9):1733-41. PubMed ID: 26285788
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular Benefit of SGLT2 Inhibitors in the Therapeutics of Diabetes Mellitus: A Close Look beyond the Horizon.
Ren DY; Zhang Y
Curr Drug Targets; 2018; 19(9):1051-1057. PubMed ID: 29848274
[TBL] [Abstract][Full Text] [Related]
12. Stronger Warning for Two Diabetes Drugs.
Aschenbrenner DS
Am J Nurs; 2016 Oct; 116(10):26. PubMed ID: 27684766
[No Abstract] [Full Text] [Related]
13. The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury.
Chu C; Lu YP; Yin L; Hocher B
Kidney Blood Press Res; 2019; 44(2):149-157. PubMed ID: 30939483
[TBL] [Abstract][Full Text] [Related]
14. Clinical implication of SGLT2 inhibitors in type 2 diabetes.
Kim GW; Chung SH
Arch Pharm Res; 2014 Aug; 37(8):957-66. PubMed ID: 24950857
[TBL] [Abstract][Full Text] [Related]
15. A Review of Sodium Glucose Co-transporter 2 Inhibitors Canagliflozin, Dapagliflozin and Empagliflozin.
Syed SH; Gosavi S; Shami W; Bustamante M; Farah Z; Teleb M; Abbas A; Said S; Mukherjee D
Cardiovasc Hematol Agents Med Chem; 2015; 13(2):105-12. PubMed ID: 26549321
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological aspects of the safety of gliflozins.
Faillie JL
Pharmacol Res; 2017 Apr; 118():71-81. PubMed ID: 27389050
[TBL] [Abstract][Full Text] [Related]
17. An update on the safety and efficacy of oral antidiabetic drugs: DPP-4 inhibitors and SGLT-2 inhibitors.
Lamos EM; Hedrington M; Davis SN
Expert Opin Drug Saf; 2019 Aug; 18(8):691-701. PubMed ID: 31150300
[TBL] [Abstract][Full Text] [Related]
18. SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment.
Scheen AJ
Expert Opin Drug Saf; 2015; 14(12):1879-904. PubMed ID: 26513131
[TBL] [Abstract][Full Text] [Related]
19. SGLT-2 Inhibitors: A Novel Mechanism in Targeting Glycemic Control in Type 2 Diabetes Mellitus.
Nathan KT; Ahmed-Sarwar N; Werner P
Consult Pharm; 2016 May; 31(5):251-60. PubMed ID: 27178654
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
Scheen AJ
Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
